The Philippines Food and Drug Administration issued Advisory No. 2026-1019-A on September 4, 2026, directing the public and all commercial establishments to cease purchasing and distributing an unregistered tirzepatide product marketed under the brand name Peptatide. Post-Marketing Surveillance verified that the drug product lacked a Certificate of Product Registration Philippines FDA Advisory No. 2026-1019-A.
The advisory applies to Peptatide Tirzepatide for Subcutaneously Use Only 15mg and Peptatide Bacteriostatic Water Reconstitution Solution containing 0.9 percent Benzyl Alcohol 15ml. Consumers who use unregistered products expose themselves to potential health risks, because the quality, safety, and efficacy of such items cannot be verified without proper registration.
The agency determined the 15mg active pharmaceutical ingredient and its 15ml diluent bypassed the statutory registration threshold. Without a Certificate of Product Registration, the Philippines FDA stated the public cannot verify the quality, safety, or efficacy of the product Philippines FDA Advisory No. 2026-1019-A. Establishments distributing the unregistered drug face regulatory actions and sanctions Philippines FDA Advisory No. 2026-1019.
The advisory explicitly warns all concerned establishments and entities not to distribute the violative drug product until an appropriate authorization has been granted by the FDA. Failure to comply with this directive will result in the strict pursuit of regulatory actions and sanctions against those who continue to sell or handle the product.
The enforcement directive mobilizes Local Government Units and Law Enforcement Agencies to prevent the sale or use of the Peptatide products within their jurisdictions Philippines FDA Advisory No. 2026-1019-A. The advisory also instructs consumers to verify product registration status through the FDA Verification Portal. This statutory registration mechanism differs from U.S. enforcement frameworks. The U.S.
FDA uses warning letters to address unapproved new drugs and misbranded products, as documented when it fda slaps 30 telehealth firms with warning letters over compounded glp-1 marketing. In the United States, regulators have been tracking hundreds of adverse-event reports tied to compounded weight-loss drugs and unapproved peptides, highlighting the global scale of the challenge surrounding these therapies.
The Philippines FDA has not published adverse event data, clinical findings, or testing results in connection with Advisory No. 2026-1019-A. The advisory does not identify the manufacturer, distributor, or country of origin for the Peptatide brand. The approved records do not establish any connection between these products and U.S. supply chains or import alerts.
However, the broader global context reveals that unapproved GLP-1 drugs used for weight loss have raised fresh safety concerns internationally, with reported symptoms including nausea, vomiting, diarrhea, abdominal pain, and constipation FDA Raises Fresh Safety Concerns Over Unapproved GLP-1 Weight-Loss Drugs. The FDA has urged healthcare professionals to carefully assess dosing and titration schedules when dealing with such compounds, advising patients to exercise extreme caution.
This administrative action applies a product registration framework to a GLP-1 analog in a Pacific market. It runs parallel to ongoing U.S. regulatory proceedings. Recent U.S. decisions on compounding access include actions where the fda splits peptide path and where a fda panel backs 6 compounded peptides as agency moves to exclude glp-1s.
The Philippines FDA maintained its online reporting facility for continued sales of the unregistered Peptatide products as of September 4 Philippines FDA Advisory No. 2026-1019-A.
Regulators around the world are intensifying their scrutiny of peptide therapies and GLP-1 receptor agonists as demand surges. In the Philippines, the FDA’s Post-Marketing Surveillance activities remain the primary mechanism for identifying unregistered drugs entering the consumer market. 2026-1019](https://www.fda.gov.ph/fda-advisory-no-2026-1019-public-health-warning-against-the-purchase-and-use-of-the-unregistered-drug-product-peptatide-tirzepatide-for-subcutaneously-use-only-15mg-and-peptatide-bacterios/).
Consequently, consumers are strongly warned that the use or consumption of violative products may expose them to potential health risks, including possible injury or harm. By coordinating with local governments and law enforcement, the Philippines FDA aims to remove these unregistered products from circulation swiftly, ensuring that public health standards are upheld across all jurisdictions.
The advisory serves as a critical reminder that regulatory registration exists precisely to protect patients from unverified medical products, and bypassing these safeguards undermines the entire public health infrastructure.
